Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 39 | 2024 | 9695 | 1.990 |
Why?
|
| Brain Ischemia | 19 | 2024 | 3047 | 1.700 |
Why?
|
| CADASIL | 6 | 2019 | 88 | 1.020 |
Why?
|
| Ischemic Attack, Transient | 8 | 2024 | 878 | 0.880 |
Why?
|
| Atrial Fibrillation | 10 | 2023 | 5105 | 0.830 |
Why?
|
| Amnesia, Transient Global | 1 | 2022 | 20 | 0.800 |
Why?
|
| Intracranial Hemorrhages | 12 | 2024 | 820 | 0.750 |
Why?
|
| Cerebral Hemorrhage | 15 | 2024 | 2650 | 0.690 |
Why?
|
| Amnesia | 1 | 2022 | 255 | 0.690 |
Why?
|
| Anticoagulants | 15 | 2024 | 4776 | 0.600 |
Why?
|
| Vertebral Artery Dissection | 3 | 2024 | 51 | 0.530 |
Why?
|
| Phantoms, Imaging | 6 | 2023 | 2509 | 0.490 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 1081 | 0.490 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2020 | 517 | 0.480 |
Why?
|
| Tranexamic Acid | 3 | 2023 | 176 | 0.470 |
Why?
|
| Frontal Lobe | 2 | 2019 | 1419 | 0.460 |
Why?
|
| Thrombolytic Therapy | 9 | 2023 | 2060 | 0.440 |
Why?
|
| Atherosclerosis | 3 | 2024 | 3401 | 0.420 |
Why?
|
| Neurofilament Proteins | 3 | 2021 | 333 | 0.410 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 8981 | 0.400 |
Why?
|
| Radiotherapy | 1 | 2018 | 1498 | 0.390 |
Why?
|
| Antifibrinolytic Agents | 4 | 2023 | 292 | 0.380 |
Why?
|
| Pre-Eclampsia | 1 | 2020 | 1226 | 0.380 |
Why?
|
| Fibrinolytic Agents | 9 | 2024 | 2070 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2023 | 20499 | 0.360 |
Why?
|
| Protons | 4 | 2023 | 1112 | 0.350 |
Why?
|
| Proteome | 1 | 2019 | 1855 | 0.320 |
Why?
|
| Carotid Artery, Internal, Dissection | 2 | 2021 | 42 | 0.310 |
Why?
|
| Dementia | 1 | 2022 | 2649 | 0.300 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2023 | 1659 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2023 | 2746 | 0.280 |
Why?
|
| Secondary Prevention | 4 | 2024 | 1474 | 0.280 |
Why?
|
| Vitamin K | 5 | 2021 | 318 | 0.270 |
Why?
|
| Migraine Disorders | 1 | 2018 | 1694 | 0.260 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2023 | 892 | 0.250 |
Why?
|
| Humans | 71 | 2024 | 757650 | 0.240 |
Why?
|
| Thrombectomy | 3 | 2024 | 690 | 0.240 |
Why?
|
| Diet | 1 | 2022 | 8003 | 0.230 |
Why?
|
| Switzerland | 5 | 2024 | 323 | 0.230 |
Why?
|
| Consensus | 2 | 2023 | 3098 | 0.220 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2024 | 50 | 0.220 |
Why?
|
| Collateral Circulation | 1 | 2024 | 292 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 11075 | 0.200 |
Why?
|
| Male | 45 | 2024 | 358227 | 0.200 |
Why?
|
| Aged | 35 | 2024 | 167889 | 0.200 |
Why?
|
| Siderosis | 1 | 2022 | 103 | 0.190 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 58559 | 0.190 |
Why?
|
| Intermediate Filaments | 1 | 2021 | 172 | 0.190 |
Why?
|
| Aspirin | 2 | 2024 | 3131 | 0.180 |
Why?
|
| Hypertension | 1 | 2020 | 8502 | 0.180 |
Why?
|
| Hemostatics | 1 | 2023 | 240 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 2414 | 0.180 |
Why?
|
| Calibration | 1 | 2023 | 813 | 0.180 |
Why?
|
| Thromboembolism | 2 | 2024 | 995 | 0.170 |
Why?
|
| Brain | 9 | 2022 | 26950 | 0.170 |
Why?
|
| Female | 43 | 2024 | 389985 | 0.170 |
Why?
|
| Uncertainty | 2 | 2021 | 750 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2024 | 479 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2023 | 400 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 2782 | 0.160 |
Why?
|
| Prospective Studies | 17 | 2024 | 54108 | 0.160 |
Why?
|
| Atrophy | 2 | 2022 | 1627 | 0.160 |
Why?
|
| Administration, Oral | 6 | 2023 | 3995 | 0.140 |
Why?
|
| Hematoma | 4 | 2024 | 768 | 0.140 |
Why?
|
| Cohort Studies | 12 | 2023 | 41198 | 0.130 |
Why?
|
| Head | 1 | 2022 | 921 | 0.130 |
Why?
|
| Radiometry | 1 | 2021 | 813 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2024 | 6525 | 0.130 |
Why?
|
| Memory Disorders | 1 | 2022 | 1198 | 0.120 |
Why?
|
| Self Report | 2 | 2023 | 3709 | 0.120 |
Why?
|
| Registries | 6 | 2022 | 8164 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2018 | 678 | 0.110 |
Why?
|
| Middle Aged | 24 | 2024 | 219219 | 0.110 |
Why?
|
| Exercise Test | 1 | 2020 | 2121 | 0.110 |
Why?
|
| Antithrombins | 1 | 2015 | 294 | 0.100 |
Why?
|
| Ubiquitin | 1 | 2017 | 837 | 0.100 |
Why?
|
| Treatment Outcome | 14 | 2024 | 64242 | 0.100 |
Why?
|
| Independent Living | 1 | 2016 | 567 | 0.100 |
Why?
|
| Cognitive Reserve | 1 | 2012 | 92 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 1314 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2017 | 960 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2019 | 1915 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2022 | 3182 | 0.090 |
Why?
|
| Risk Factors | 9 | 2024 | 73716 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2022 | 39018 | 0.090 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 549 | 0.080 |
Why?
|
| Hippocampus | 1 | 2022 | 3739 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 682 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 36271 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 3227 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 2139 | 0.080 |
Why?
|
| Cerebral Infarction | 2 | 2024 | 982 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 11893 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 809 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2015 | 853 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2011 | 743 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2018 | 3399 | 0.060 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2011 | 952 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 13464 | 0.060 |
Why?
|
| Proteomics | 1 | 2019 | 3816 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2007 | 290 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 1426 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2016 | 2155 | 0.060 |
Why?
|
| Germany | 2 | 2021 | 865 | 0.060 |
Why?
|
| Recurrence | 3 | 2021 | 8426 | 0.050 |
Why?
|
| Factor Xa | 1 | 2024 | 167 | 0.050 |
Why?
|
| Stents | 1 | 2015 | 3162 | 0.050 |
Why?
|
| Meninges | 1 | 2024 | 197 | 0.050 |
Why?
|
| Prognosis | 5 | 2023 | 29493 | 0.050 |
Why?
|
| Vasospasm, Intracranial | 1 | 2024 | 215 | 0.050 |
Why?
|
| Phenprocoumon | 1 | 2021 | 20 | 0.050 |
Why?
|
| Acenocoumarol | 1 | 2021 | 19 | 0.050 |
Why?
|
| Hospital Distribution Systems | 1 | 2020 | 5 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2022 | 141 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2024 | 79982 | 0.040 |
Why?
|
| Europe | 2 | 2019 | 3415 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2020 | 152 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2020 | 312 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2020 | 332 | 0.040 |
Why?
|
| Arteries | 1 | 2024 | 1125 | 0.040 |
Why?
|
| Pregnancy | 1 | 2020 | 29720 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 759 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 90 | 0.040 |
Why?
|
| Thrombocytosis | 1 | 2018 | 81 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 13267 | 0.040 |
Why?
|
| Chromogenic Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 579 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 850 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2023 | 1156 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2011 | 3975 | 0.040 |
Why?
|
| Acute Disease | 2 | 2019 | 7226 | 0.030 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2019 | 306 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2017 | 198 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2017 | 23342 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 25931 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2011 | 6571 | 0.030 |
Why?
|
| Inflammation | 1 | 2016 | 10718 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2021 | 12260 | 0.030 |
Why?
|
| Adult | 9 | 2024 | 219747 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 3338 | 0.030 |
Why?
|
| Horner Syndrome | 1 | 2015 | 36 | 0.030 |
Why?
|
| Self Administration | 1 | 2016 | 390 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 842 | 0.030 |
Why?
|
| Platelet Count | 1 | 2018 | 774 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 2015 | 112 | 0.030 |
Why?
|
| Diagnosis | 1 | 2016 | 156 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 2015 | 267 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 745 | 0.030 |
Why?
|
| Incidence | 3 | 2019 | 21217 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 341 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 2895 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 20039 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1003 | 0.030 |
Why?
|
| Time Factors | 4 | 2017 | 39815 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2013 | 6336 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 940 | 0.030 |
Why?
|
| Warfarin | 1 | 2021 | 1483 | 0.030 |
Why?
|
| Sulfhydryl Reagents | 1 | 2011 | 32 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2017 | 12761 | 0.020 |
Why?
|
| Maleimides | 1 | 2011 | 113 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 193 | 0.020 |
Why?
|
| Axons | 1 | 2018 | 1674 | 0.020 |
Why?
|
| Netherlands | 1 | 2015 | 2212 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 428 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 1173 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 491 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9590 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 1743 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 7024 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10750 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2011 | 695 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 2011 | 685 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2018 | 3040 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 4624 | 0.020 |
Why?
|
| France | 1 | 2008 | 499 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3774 | 0.020 |
Why?
|
| tau Proteins | 1 | 2017 | 2085 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 15782 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 29928 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2011 | 979 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5195 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5782 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9245 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12685 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 2152 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10075 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 7584 | 0.010 |
Why?
|
| Educational Status | 1 | 2012 | 2511 | 0.010 |
Why?
|
| Computational Biology | 1 | 2016 | 3501 | 0.010 |
Why?
|
| Executive Function | 1 | 2012 | 1375 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2016 | 6363 | 0.010 |
Why?
|
| Memory | 1 | 2012 | 2179 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6469 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8551 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4258 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8601 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13222 | 0.010 |
Why?
|
| Cytokines | 1 | 2016 | 7339 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 4047 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2008 | 2880 | 0.010 |
Why?
|
| Quality of Life | 1 | 2019 | 13265 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12047 | 0.010 |
Why?
|
| Cognition | 1 | 2012 | 6955 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14638 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2015 | 15532 | 0.010 |
Why?
|
Concepts
(205)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_